Stockreport

Motif Bio Announces Notice of Allowance for Two U.S. Iclaprim Patents with Expiration in 2037

MOTIF BIO PLC ADRS  (MTFB) 
US:NASDAQ Investor Relations: ir.motifbio.com
PDF NEW YORK, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB) ("Motif Bio" or the "Company"), a clinical-stage biopharmaceutical company specialising in [Read more]